// COMPANY
Delix Therapeutics
SECTOR BIOTECHMENTIONS 2LAST SEEN AUGUST 25, 2026
Discussed in
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
funding·StrictlyVC·AUGUST 25, 2026
“Raised $85M Series C led by Johnson & Johnson; represents growing institutional pharma interest in psychedelic-adjacent therapeutics without the regulatory complexity of hallucinogens.”
Source→02
funding·Axios Pro Rata·AUGUST 24, 2026
“Delix Therapeutics, a Boston-based developer of psychoplastogens, raised $85m in Series C funding led by J&J.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.